Klinik Hietzing

The clinic explores innovative approaches to combat bacterial infections and fungal diseases, aiming to improve treatment outcomes and reduce resistance.

• Evaluation of novel antimicrobial agents
• Assessment of diagnostic biomarkers for infection severity
• Safety profiling of combination therapies

While this therapeutic area accounts for a smaller portion of the 14 active studies, the expertise of the Karl Landsteiner Institute supports rigorous investigation.

Research at Klinik Hietzing targets cardiovascular disease risk reduction, focusing on atherosclerotic conditions and elevated lipoprotein(a).

• Trials assessing lipid‑lowering therapies in ASCVD
• Studies on cardiovascular outcomes in patients with obesity
• Investigations of novel agents to prevent coronary events

Several of the 14 trials evaluate heart‑related endpoints, reflecting the site’s commitment to advancing cardiovascular health.

The department conducts studies on disorders of the immune system, including inflammatory skin conditions and systemic immune dysregulation.

• Rocatinlimab combined with topical therapy for atopic dermatitis
• Spesolimab evaluation in hidradenitis suppurativa
• Safety monitoring of immune‑modulating agents

Immune‑focused trials represent a key pillar of the site’s research portfolio, leveraging its expertise in both dermatology and systemic immunity.

Oncology investigations concentrate on breast cancer subtypes and strategies to prevent recurrence after standard therapy.

• Camizestrant plus endocrine therapy in ER+/HER2‑ negative early breast cancer
• Imlunestrant versus standard endocrine treatment
• Extended endocrine therapy to reduce breast cancer relapse

The institute’s oncology program contributes multiple trials aimed at improving long‑term outcomes for patients with neoplastic disease.

Studies address metabolic disorders such as obesity, overweight, and severe hypertriglyceridemia, seeking to modulate key metabolic pathways.

• Pegozafermin effects on fasting triglyceride levels
• Orforglipron compared with insulin glargine for cardiovascular risk
• Tirzepatide impact on morbidity and mortality in obesity

Metabolic research is a central focus, with several trials evaluating novel agents that target weight and lipid metabolism.

The site investigates progressive lung conditions, emphasizing therapies that preserve lung function and slow disease progression.

• BMS‑986278 safety and efficacy in idiopathic pulmonary fibrosis
• Admilparant trials measuring forced vital capacity in progressive pulmonary fibrosis
• Exploration of anti‑fibrotic mechanisms in chronic respiratory disease

Respiratory trials contribute to the broader effort to improve quality of life for patients with debilitating lung disorders.

Investigations aim to enhance treatment options for dermatologic conditions such as atopic dermatitis and hidradenitis suppurativa.

• Rocatinlimab combined with topical corticosteroids for moderate‑to‑severe AD
• Spesolimab dose‑finding and confirmatory studies in hidradenitis suppurativa
• Patient‑reported outcome measures for skin disease severity

The dermatology program leverages the institute’s expertise to advance therapies that target skin inflammation and tissue integrity.

Research explores fundamental metabolic processes, linking them to conditions such as chronic kidney disease and type 2 diabetes.

• Tirzepatide effects on kidney oxygenation in participants with and without T2D
• Orforglipron’s role in cardiovascular risk management for diabetic patients
• Metabolic biomarkers used to assess treatment response

By focusing on core metabolic pathways, the institute supports translational studies that bridge basic science and clinical application.